Press Release

Sept. 23, 2019FDA Grants Pediatric Disease Designation for Mateon’s OT101
Sept. 9, 2019Mateon Partners With WideTrial for Data-Generating Expanded Access Programs in Cancer
Aug. 19, 2019Mateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of Cancer
July 30, 2019Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical Testing
July 16, 2019Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic
June 12, 2019Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board
June 10, 2019Mateon and Oncotelic Report on Continuing Integration of the two Businesses
June 3, 2019WideTrial Partners With Oncotelic to Bring Expanded Access Platform to Cancer
May. 15, 2019Mateon Reports First Quarter 2019 Financial Results
Apr. 25, 2019Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
Mar. 04, 2019Oncotelic Reports Clinical Validation of Drug Induce Xenogenization (DIX) For Treatment of Glioblastoma and Pancreatic Cancer (PC)
Feb. 13, 2019Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
Jan. 22, 2019Oncotelic Inc. Announces Appointment of Fatih Uckun MD PhD to Chief Medical Officer
Oct. 10, 2018OT-101 (Trabedersen) a TGF-beta2 Specific Inhibitor As Immuno Oncology Agent Against Glioblastoma
Mar. 30, 2017Oncotelic and Autotelic Inc. Present to Present Data on OT-101 Program at 2017 American Association for Cancer Research Annual Meeting
Jan. 18, 2017Oncotelic and Autotelic Inc. Present Clinical Data at 2017 GI Cancer Symposium to Support IL-8 Positive Association with Survival Improved Overall Survival in Advanced Pancreatic Cancer treated with Trabedersen (OT-101)
Sept. 25-28, 2016Dr. Larn Hwang, CEO, will present the poster entitled 'Impact of Antisense OT-101 Therapy on the Cytokine and Chemokine Profile in Patients with Pancreatic Cancer' on September 26th, 2016 at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada.
Mar. 10-12, 2016Dr. Larn Hwang, CEO, will be presenting the poster entitled "Treatment with Trabedersen- an anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies" at The 3rd St. Gallen International Gastrointestinal Cancer Conference, St. Gallen, Switzerland.
Sept. 1-6, 2016Dr. Larn Hwang, CEO, will conduct oral presentation titled 'Cytokine Induction by Trabedersen (OT-101) Treatment - Results from a Phase I/II Trial in Pancreatic Cancer Patients' on September 4th, 2016 at the 43rd International Society of Oncology and Biomarkers (ISOBM) Congress in Chicago, IL.
Feb. 19-21, 2016Li Huang, Sr. Scientist/Biostatistics, will be presenting the poster entitled “Synergistic anti-tumor activity of OT-101, a TGF- 2 inhibitor, and Dacarbazine against C8161 human melanoma xenograft in athymic nude mice" at The 10th Canadian Melanoma Conference, Whistler, British Columbia, Canada.
Oct. 14, 2015 (BUSINESS WIRE)--Isarna Therapeutics, the leader in transforming growth factor beta (TGF-β) isoform targeted antisense therapeutics, and Autotelic Inc., a specialist in therapeutic drug monitoring and development, today announced an asset sale and purchase agreement for trabedersen, Isarna’s TGF-β2 antisense oligonucleotide. Autotelic acquires full and worldwide rights to develop trabedersen, which had previously reached Phase 3 clinical evaluation to treat recurrent high-grade glioma. No financial details of the agreement have been disclosed.